Expression and clinical significance of ghrelin in endometrial hyperplasia and carcinoma of egyptian patients

Sheren Fouad Younes, Hayam Aiad, Mona Kandil, Fatma Samir El Kalashy

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Endometrial carcinoma ranks the seventh most common malignant tumor worldwide. The distinction between atypical endometrial hyperplasia (AEH) and endometrial carcinoma, especially the well-differentiated grade, is particularly difficult with overlapping distinguishing criteria and small biopsy. Ghrelin is 28 amino acid peptide that is synthesized by gastric mucosa and is expressed in a variety of normal and tumor tissues. In endometrial tissue, it is expressed during the menstrual cycle, involved in the uterine development and cyclic growth. Data regarding role of Ghrelin in endometrial carcinoma are contradictory. In the present study, immunohistochemical expression of Ghrelin was evaluated in 55 endometrioid carcinoma cases, as well as 26 endometrial hyperplasia cases. The relationship between Ghrelin expression and clinicopathologic features of endometrioid carcinoma was studied as well. Ghrelin loss or reduced expression was significantly related to endometrioid carcinoma, especially the well-differentiated type, compared with AEH and EIN (p=0.000 and 0.006, respectively). Ghrelin loss was also related to poorly differentiated histologic grades of endometrioid carcinoma (p=0.04). Ghrelin loss is helpful in differentiation between AEH and EIN from endometrioid adenocarcinoma, especially the well-differentiated grade. It could be also related to poor differentiation.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalUltrastructural Pathology
Volume39
Issue number3
DOIs
Publication statusPublished - 1 Jan 2015

Fingerprint

Endometrial Hyperplasia
Ghrelin
Endometrial Neoplasms
Endometrioid Carcinoma
Menstrual Cycle
Gastric Mucosa
Growth and Development
Neoplasms
Biopsy
Amino Acids
Peptides

Keywords

  • Endometrial carcinoma
  • Ghrelin
  • Immunohistochemistry

Cite this

@article{5d5e8359d1ef4e8089fd85435d8b85f2,
title = "Expression and clinical significance of ghrelin in endometrial hyperplasia and carcinoma of egyptian patients",
abstract = "Endometrial carcinoma ranks the seventh most common malignant tumor worldwide. The distinction between atypical endometrial hyperplasia (AEH) and endometrial carcinoma, especially the well-differentiated grade, is particularly difficult with overlapping distinguishing criteria and small biopsy. Ghrelin is 28 amino acid peptide that is synthesized by gastric mucosa and is expressed in a variety of normal and tumor tissues. In endometrial tissue, it is expressed during the menstrual cycle, involved in the uterine development and cyclic growth. Data regarding role of Ghrelin in endometrial carcinoma are contradictory. In the present study, immunohistochemical expression of Ghrelin was evaluated in 55 endometrioid carcinoma cases, as well as 26 endometrial hyperplasia cases. The relationship between Ghrelin expression and clinicopathologic features of endometrioid carcinoma was studied as well. Ghrelin loss or reduced expression was significantly related to endometrioid carcinoma, especially the well-differentiated type, compared with AEH and EIN (p=0.000 and 0.006, respectively). Ghrelin loss was also related to poorly differentiated histologic grades of endometrioid carcinoma (p=0.04). Ghrelin loss is helpful in differentiation between AEH and EIN from endometrioid adenocarcinoma, especially the well-differentiated grade. It could be also related to poor differentiation.",
keywords = "Endometrial carcinoma, Ghrelin, Immunohistochemistry",
author = "Younes, {Sheren Fouad} and Hayam Aiad and Mona Kandil and {El Kalashy}, {Fatma Samir}",
year = "2015",
month = "1",
day = "1",
doi = "10.3109/01913123.2014.983627",
language = "English",
volume = "39",
pages = "207--213",
journal = "Ultrastructural Pathology",
issn = "0191-3123",
publisher = "Informa Healthcare",
number = "3",

}

Expression and clinical significance of ghrelin in endometrial hyperplasia and carcinoma of egyptian patients. / Younes, Sheren Fouad; Aiad, Hayam; Kandil, Mona; El Kalashy, Fatma Samir.

In: Ultrastructural Pathology, Vol. 39, No. 3, 01.01.2015, p. 207-213.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Expression and clinical significance of ghrelin in endometrial hyperplasia and carcinoma of egyptian patients

AU - Younes, Sheren Fouad

AU - Aiad, Hayam

AU - Kandil, Mona

AU - El Kalashy, Fatma Samir

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Endometrial carcinoma ranks the seventh most common malignant tumor worldwide. The distinction between atypical endometrial hyperplasia (AEH) and endometrial carcinoma, especially the well-differentiated grade, is particularly difficult with overlapping distinguishing criteria and small biopsy. Ghrelin is 28 amino acid peptide that is synthesized by gastric mucosa and is expressed in a variety of normal and tumor tissues. In endometrial tissue, it is expressed during the menstrual cycle, involved in the uterine development and cyclic growth. Data regarding role of Ghrelin in endometrial carcinoma are contradictory. In the present study, immunohistochemical expression of Ghrelin was evaluated in 55 endometrioid carcinoma cases, as well as 26 endometrial hyperplasia cases. The relationship between Ghrelin expression and clinicopathologic features of endometrioid carcinoma was studied as well. Ghrelin loss or reduced expression was significantly related to endometrioid carcinoma, especially the well-differentiated type, compared with AEH and EIN (p=0.000 and 0.006, respectively). Ghrelin loss was also related to poorly differentiated histologic grades of endometrioid carcinoma (p=0.04). Ghrelin loss is helpful in differentiation between AEH and EIN from endometrioid adenocarcinoma, especially the well-differentiated grade. It could be also related to poor differentiation.

AB - Endometrial carcinoma ranks the seventh most common malignant tumor worldwide. The distinction between atypical endometrial hyperplasia (AEH) and endometrial carcinoma, especially the well-differentiated grade, is particularly difficult with overlapping distinguishing criteria and small biopsy. Ghrelin is 28 amino acid peptide that is synthesized by gastric mucosa and is expressed in a variety of normal and tumor tissues. In endometrial tissue, it is expressed during the menstrual cycle, involved in the uterine development and cyclic growth. Data regarding role of Ghrelin in endometrial carcinoma are contradictory. In the present study, immunohistochemical expression of Ghrelin was evaluated in 55 endometrioid carcinoma cases, as well as 26 endometrial hyperplasia cases. The relationship between Ghrelin expression and clinicopathologic features of endometrioid carcinoma was studied as well. Ghrelin loss or reduced expression was significantly related to endometrioid carcinoma, especially the well-differentiated type, compared with AEH and EIN (p=0.000 and 0.006, respectively). Ghrelin loss was also related to poorly differentiated histologic grades of endometrioid carcinoma (p=0.04). Ghrelin loss is helpful in differentiation between AEH and EIN from endometrioid adenocarcinoma, especially the well-differentiated grade. It could be also related to poor differentiation.

KW - Endometrial carcinoma

KW - Ghrelin

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=84928895671&partnerID=8YFLogxK

U2 - 10.3109/01913123.2014.983627

DO - 10.3109/01913123.2014.983627

M3 - Article

VL - 39

SP - 207

EP - 213

JO - Ultrastructural Pathology

JF - Ultrastructural Pathology

SN - 0191-3123

IS - 3

ER -